{
    "clinical_study": {
        "@rank": "48632", 
        "acronym": "FLAGSHIP", 
        "arm_group": [
            {
                "arm_group_label": "AQX-1125", 
                "arm_group_type": "Experimental", 
                "description": "1 x AQX-1125 capsule daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 x Placebo capsule daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the effect of 12 weeks of treatment with\n      once daily administration of AQX-1125 compared to placebo in subjects following\n      exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src\n      Homology 2-containing Inositol-5'-Phosphatase 1) pathway."
        }, 
        "brief_title": "Efficacy and Safety of AQX-1125 in Unstable COPD", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female aged \u226540 years at screening\n\n          2. History of COPD for at least 18 months prior to screening, characterised by excessive\n             sputum production\n\n          3. Chronic productive cough for at least 3 months in each of the 2 years prior to\n             screening (if other causes of productive cough have been excluded) and/or an\n             exacerbation of COPD with predominantly bronchitic symptoms at enrolment\n\n          4. At least 2 documented exacerbations during the last 18 months prior to screening.\n\n          5. Presentation of a diagnosed acute exacerbation of COPD, or have recently (within 3\n             days) been discharged from hospital due to an acute exacerbation of COPD\n\n          6. Ability to perform pulmonary function testing and with documented fixed airway\n             obstruction determined by an FEV1 /FVC [forced vital capacity] ratio\n             (post-bronchodilator) of <0.70 and a predicted FEV1 value of 30%-80% of normal within\n             the 6 months prior to Visit 1.\n\n          7. Former smoker or current smoker, both with a smoking history of at least 10 pack\n             years\n\n        Exclusion Criteria:\n\n          1. Diagnosis of other relevant lung disease (e.g. asthma, cystic fibrosis [CF] or\n             significant non-CF bronchiectasis)\n\n          2. Known alpha-1-antitrypsin deficiency\n\n          3. Treatment with roflumilast or theophylline within 1 month prior to screening\n\n          4. Lobar pneumonia, with current positive chest X-ray (CXR) or within the 3 months prior\n             to screening including the presence of any new radiological infiltrate on CXR within\n             the previous two weeks\n\n          5. Hospitalisation for more than 7 days for current acute exacerbation, or the\n             requirement for intubation during hospitalisation\n\n          6. For outpatients, prior medical history indicating that previous exacerbations\n             required >3 weeks to stabilise"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954628", 
            "org_study_id": "AQX-1125-202"
        }, 
        "intervention": [
            {
                "arm_group_label": "AQX-1125", 
                "description": "Synthetic SHIP1 activator", 
                "intervention_name": "AQX-1125", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo control", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Exacerbation of COPD", 
            "Unstable COPD"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "GOLD COPD Guidelines", 
            "url": "http://www.goldcopd.org/Guidelines/guidelines-resources.html"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wentworthville", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2145"
                    }, 
                    "name": "Department of Respiratory & Sleep Medicine, Westmead Hospital"
                }, 
                "investigator": {
                    "last_name": "John Wheatley, MD, PhD, FRACP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J\u00f8rgen Vestbo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark"
                    }, 
                    "name": "Department of Respiratory Medicine, Odense University Hospital"
                }, 
                "investigator": {
                    "last_name": "J\u00f8rgen Vestbo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ari Lindqvist, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "Biomedicum Helsinki"
                }, 
                "investigator": {
                    "last_name": "Pekka Saarelainen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Beatrix Ballint, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Deszk", 
                        "country": "Hungary"
                    }, 
                    "name": "Csongr\u00e1d Megyei Melkasi Betegs\u00e9gek Szakk\u00f3rh\u00e1za"
                }, 
                "investigator": {
                    "last_name": "Beatrix Balint, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Piotr Kuna, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland"
                    }, 
                    "name": "Medical University of Lodz"
                }, 
                "investigator": {
                    "last_name": "Piotr Kuna, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Leif Bjermer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }, 
                    "name": "Lung and Allergy Clinic, Sk\u00e5ne University Hospital"
                }, 
                "investigator": {
                    "last_name": "Leif Bjermer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Denmark", 
                "Finland", 
                "Hungary", 
                "Poland", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway", 
        "other_outcome": {
            "description": "The secondary objectives are to evaluate the pharmacokinetics (PK) of AQX-1125 in plasma", 
            "measure": "AQX-1125 concentrations in plasma (trough values)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "last_name": "Veena Kalia, PhD", 
            "phone": "604 629 9223", 
            "phone_ext": "133"
        }, 
        "overall_contact_backup": {
            "last_name": "Stephen B Shrewsbury, MD", 
            "phone": "604 629 9223", 
            "phone_ext": "107"
        }, 
        "overall_official": {
            "affiliation": "Aquinox Pharmaceuticals, Inc.", 
            "last_name": "Stephen B Shrewsbury, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Finland: Finnish Medicines Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Hungary: National Institute of Pharmacy", 
                "Poland: The Central Register of Clinical Trials", 
                "Australia: Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on recurrent exacerbations as measured by EXACT (EXAcerbation of Chronic pulmonary disease Tool) in subjects with COPD following a recent exacerbation.", 
            "measure": "Change from baseline in EXACT score", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the COPD Assessment Tool (CAT) score", 
                "measure": "Change from baseline in CAT score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on forced expiratory volume in 1 second [FEV1]", 
                "measure": "Change from baseline in FEV1", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The secondary objectives are to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the frequency and severity of adverse events (AEs) and changes in, physical examination, vital signs, ophthalmic examination, laboratory tests, weight, electrocardiogram (ECG), and concomitant medications", 
                "measure": "Safety determined by adverse events [AEs], physical examinations, laboratory tests, electrocardiogram [ECG] and ophthalmic examinations", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Aquinox Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aquinox Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}